Current and future treatment options in osteoporosis.

Hdl Handle:
http://hdl.handle.net/10147/126082
Title:
Current and future treatment options in osteoporosis.
Authors:
Brewer, Linda; Williams, David; Moore, Alan
Affiliation:
General and Geriatric Medicine, Beaumont Hospital, Dublin, Ireland, lindabrewer@physicians.ie.
Citation:
Current and future treatment options in osteoporosis. 2011, 67 (4):321-31 Eur. J. Clin. Pharmacol.
Journal:
European journal of clinical pharmacology
Issue Date:
Apr-2011
URI:
http://hdl.handle.net/10147/126082
DOI:
10.1007/s00228-011-0999-2
PubMed ID:
21327420
Additional Links:
http://www.springerlink.com/content/bv57684005j00hg8/
Abstract:
The incidence of osteoporosis-related fractures will increase substantially over the coming decades as the population ages globally. This has important economic and public health implications, contributing substantially to morbidity and excess mortality in this population.; When prescribing for older patients the effectiveness profile of drugs needs to be balanced against their tolerability in individual patients.; Currently we have good anti-fracture data to support the use of many available anti-resorptive and anabolic drugs including bisphosphonates, strontium ranelate and recombinant human parathyroid hormone. We also have evidence to demonstrate the importance of calcium and vitamin D repletion in these patients. However, in recent years our understanding of normal bone physiology and the mechanisms underlying the development of osteoporosis has significantly advanced and this has led to the development of new therapies. Novel agents, particularly denosumab, but also inhibitors of cathepsin K and anabolic agents that act on Wnt signalling, will increase the therapeutic options for clinicians in the coming years.; This review discusses the evidence supporting the use of currently available treatment options for osteoporosis and potential future advances in drug therapy. Particular consideration should be given when prescribing for certain older patients who have issues with compliance or tolerance and also in those with co-morbidities or levels of frailty that may restrict the choice of therapy. Understanding the evidence for the benefit and possible harm of osteoporosis treatments is critical to appropriate management of this patient population.
Item Type:
Article In Press
Language:
en
ISSN:
1432-1041

Full metadata record

DC FieldValue Language
dc.contributor.authorBrewer, Lindaen
dc.contributor.authorWilliams, Daviden
dc.contributor.authorMoore, Alanen
dc.date.accessioned2011-03-29T14:02:45Z-
dc.date.available2011-03-29T14:02:45Z-
dc.date.issued2011-04-
dc.identifier.citationCurrent and future treatment options in osteoporosis. 2011, 67 (4):321-31 Eur. J. Clin. Pharmacol.en
dc.identifier.issn1432-1041-
dc.identifier.pmid21327420-
dc.identifier.doi10.1007/s00228-011-0999-2-
dc.identifier.urihttp://hdl.handle.net/10147/126082-
dc.description.abstractThe incidence of osteoporosis-related fractures will increase substantially over the coming decades as the population ages globally. This has important economic and public health implications, contributing substantially to morbidity and excess mortality in this population.-
dc.description.abstractWhen prescribing for older patients the effectiveness profile of drugs needs to be balanced against their tolerability in individual patients.-
dc.description.abstractCurrently we have good anti-fracture data to support the use of many available anti-resorptive and anabolic drugs including bisphosphonates, strontium ranelate and recombinant human parathyroid hormone. We also have evidence to demonstrate the importance of calcium and vitamin D repletion in these patients. However, in recent years our understanding of normal bone physiology and the mechanisms underlying the development of osteoporosis has significantly advanced and this has led to the development of new therapies. Novel agents, particularly denosumab, but also inhibitors of cathepsin K and anabolic agents that act on Wnt signalling, will increase the therapeutic options for clinicians in the coming years.-
dc.description.abstractThis review discusses the evidence supporting the use of currently available treatment options for osteoporosis and potential future advances in drug therapy. Particular consideration should be given when prescribing for certain older patients who have issues with compliance or tolerance and also in those with co-morbidities or levels of frailty that may restrict the choice of therapy. Understanding the evidence for the benefit and possible harm of osteoporosis treatments is critical to appropriate management of this patient population.-
dc.language.isoenen
dc.relation.urlhttp://www.springerlink.com/content/bv57684005j00hg8/en
dc.titleCurrent and future treatment options in osteoporosis.en
dc.typeArticle In Pressen
dc.contributor.departmentGeneral and Geriatric Medicine, Beaumont Hospital, Dublin, Ireland, lindabrewer@physicians.ie.en
dc.identifier.journalEuropean journal of clinical pharmacologyen
dc.description.provinceLeinster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.